AbCellera Biologics (ABCL) Capital Expenditures (2020 - 2026)

AbCellera Biologics' Capital Expenditures history runs 7 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• Quarterly Capital Expenditures fell 63.98% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.0 million (down 44.57% YoY) and the FY2025 annual result came in at $42.8 million, down 45.44% from the prior year.
• Capital Expenditures was $3.8 million for Q1 2026 at AbCellera Biologics, down from $9.8 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $31.3 million in Q2 2022 and bottomed at $3.8 million in Q1 2026.
• A 5-year average of $16.0 million and a median of $14.5 million in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures soared 297.78% — and 2026, when it tumbled 63.98%.
• AbCellera Biologics' Capital Expenditures stood at $12.3 million in 2022, then advanced by 17.04% to $14.4 million in 2023, then increased by 8.31% to $15.6 million in 2024, then slumped by 37.02% to $9.8 million in 2025, then plunged by 61.08% to $3.8 million in 2026.
• Business Quant data shows ABCL's Capital Expenditures at $3.8 million in Q1 2026, $9.8 million in Q4 2025, and $8.9 million in Q3 2025.